Standout Papers

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and ... 2000 2026 2008 2017 3.6k
  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck (2006)
    James A. Bonner, Paul M. Harari et al. New England Journal of Medicine
  2. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival (2009)
    James A. Bonner, Paul M. Harari et al. The Lancet Oncology
  3. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 (2018)
    Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology
  4. Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin (2000)
    José Baselga, David G. Pfister et al. Journal of Clinical Oncology
  5. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer (2011)
    Razelle Kurzrock, Steven I. Sherman et al. Journal of Clinical Oncology
  6. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer (2017)
    Stephen Bagley, Shawn Kothari et al. Lung Cancer
  7. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study (2017)
    Chiun Hsu, Se‐Hoon Lee et al. Journal of Clinical Oncology

Immediate Impact

14 by Nobel laureates 6 from Science/Nature 98 standout
Sub-graph 1 of 20

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Head and neck cancer
2021 Standout
12 intermediate papers

Works of Roger B. Cohen being referenced

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
2009 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
and 7 more

Author Peers

Author Last Decade Papers Cites
Roger B. Cohen 9018 5780 5350 320 17.1k
Ezra E.W. Cohen 8308 5492 4585 416 16.4k
Barbara Burtness 8322 4857 4301 357 15.4k
David Raben 6676 5462 4350 234 14.9k
Jacek Jassem 11155 7771 4695 510 19.3k
William E. Gooding 7327 4247 4929 282 16.9k
Paul M. Harari 8412 7072 4652 300 17.7k
Christine H. Chung 5519 3539 4635 254 15.2k
Lisa Licitra 7832 4122 2967 443 15.4k
Lillian L. Siu 11372 6417 8050 570 24.0k
Jan B. Vermorken 6896 3006 3333 365 12.5k

All Works

Loading papers...

Rankless by CCL
2026